Adicet Bio

2wks agoRelease 1 0 0

The Investor Relations website contains information about Adicet Bio's business for stockholders, potential investors, and financial analysts.

Language:
en
Collection time:
2024-12-14
Adicet BioAdicet Bio
Adicet Bio

The Investor Relations website contains information about Adicet Bio’s business for stockholders, potential investors, and financial analysts.

Table:

Catehead outry Details
Main Navigation Skip to main navigation
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio News Adicet Pops Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
Adicet Bio News Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
Webcasts Jefferies London Healthcare Conference: Watch Webcast
Webcasts Guggenheim Securities Healthcare Innovation Conference: Watch Webcast
Webcasts ADI-001 Clinical Biomarker Data: Demonstrating Robust Trafficking and CD19+ B Cell Depletion in Tissue: Watch Webcast
Set money inor Giftation Set money inor Giftation
Print Options Print
Email Alerts Email Alerts
Set money inor Contacts Set money inor Contacts
Set money inor Resources Set money inors Press Releases Giftations &I’mp; Events Stock Let knowation Corporate Governance Financial Let knowation Set money inor Resources
Corporate Governance Governance Highlights Leadership and Board of Directors
Stock Let knowation Stock Quote &I’mp; Chart Analyst Coverage
Financial Let knowation Financial Let knowation
Set money inor Resources Set money inor FAQs Let knowation Wonder Email Alerts Set money inor Contacts
About Leadership Board of Directors Scientific Advisory Board
Science GI’mma Delta T Cells Targeting Moieties Proprietary Cell Platform Pipeline
Pipeline Pipeline Expanded Access Policy Giftations and Publications Set money inors Overview
Careers Careers Join Our TeI’m Current Popings
Contact Contact
Webtake a seate Plan Hane Chow, Inc.

Introduction to the Adicet Bio Webtake a seate::

Adicet Bio is making significant strides in the field of immunotherapy, with a focus on innovative treatments for autoimmune diseases and cancer. Their ADI-270 and ADI-001 clinical trials are dracome out on topg attention, proposeing hope to patients with metastatic renal cancer and lupus nephritis. Set money inors and healthcare professionals can stick around touch oned with regular updates, tableations, and webcasts. Planed for both scientific and put my money where my mouth isor communities, the take a seate provides comprehensive access to vital resources and corporate head outvernance details.

Registrar Creation Date Server IP Registrant Email
GoDaddy.com, LLC 2014-08-28 22:22:18 23.32.39.149 abuse@godaddy.com
Adicet Bio

Ranking

Global Rank
#N/A
Worldwide
Country Rank
#N/A
Category Rank
#N/A

Visits Over Time

  • All Traffic
Bounce Rate
9.75%
Pages per Visit
1.72
Monthly Visits
404.000
Avg. Visit Duration
00:00:03

Top Keywords

  • Worldwide
  • Desktop Only
Keyword
Traffic
Volume
adicet bio
46.00
3.56 K
--

Geography

  • Desktop Only
Top 5 Countries
Country
United States
100.00%

Traffic Sources

  • Worldwide
  • Desktop Only
Marketing Mix
Source
Search
48.69%
Direct
34.58%
Social
10.80%
Referrals
5.19%
Paid Referrals
0.70%
Mail
0.04%

data statistics

Data evaluation

Adicet Bio has received 1 views on this website ;The Adicet Bio data provided on this website is an estimate and is for reference only! The actual IP, PV, bounce rate and other data shall be subject to the official data!

About Adicet BioSpecial statement

The Adicet Bio provided by APP Picks on this site are all from the Internet. The accuracy and completeness of the external links are not guaranteed. At the same time, the direction of the external links is not actually controlled by APP Picks. When 12/14/2024 4:31 PM was included, the content on the webpage was compliant and legal. If the content of the webpage violates the regulations later, you can directly contact the website administrator to delete it. APP Picks does not assume any responsibility.

Relevant Navigation

No comments

none
No comments...